Decheng Capital LLC Lowers Stock Position in 4D Molecular Therapeutics, Inc. $FDMT

Decheng Capital LLC cut its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 61.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 92,748 shares of the company’s stock after selling 146,762 shares during the quarter. 4D Molecular Therapeutics accounts for about 0.1% of Decheng Capital LLC’s holdings, making the stock its 18th biggest holding. Decheng Capital LLC owned approximately 0.16% of 4D Molecular Therapeutics worth $806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Federated Hermes Inc. raised its position in shares of 4D Molecular Therapeutics by 33.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company’s stock valued at $6,186,000 after buying an additional 417,157 shares in the last quarter. Millennium Management LLC grew its position in 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after acquiring an additional 213,264 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in 4D Molecular Therapeutics in the third quarter worth $1,556,000. Raymond James Financial Inc. increased its stake in 4D Molecular Therapeutics by 54.7% in the second quarter. Raymond James Financial Inc. now owns 455,470 shares of the company’s stock valued at $1,690,000 after acquiring an additional 161,091 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in 4D Molecular Therapeutics by 62.8% in the second quarter. Marshall Wace LLP now owns 257,620 shares of the company’s stock valued at $956,000 after acquiring an additional 99,332 shares during the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Down 1.4%

Shares of NASDAQ:FDMT opened at $8.33 on Monday. The stock has a market capitalization of $475.89 million, a P/E ratio of -2.22 and a beta of 2.99. The stock’s 50-day moving average price is $8.63 and its 200-day moving average price is $9.06. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.23 and a 12-month high of $12.34.

Wall Street Analyst Weigh In

FDMT has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Barclays assumed coverage on 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective on the stock. Chardan Capital reissued a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, December 18th. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 7th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.67.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.